Zobrazeno 1 - 10
of 67
pro vyhledávání: '"G. Bonciarelli"'
Autor:
M.V. Dieci, V. Guarneri, M. Mion, G. Tortora, P. Morandi, S. Gori, L. Merlini, C. Oliani, F. Pasini, G. Bonciarelli, E. Orvieto, P. Del Bianco, G.L. De Salvo, P.F. Conte
Publikováno v:
Annals of Oncology. 27:vi53
Autor:
Carlo Maurizio Camaggi, Andrea Martoni, Elena Strocchi, S. Miseria, G. Robustelli Della Cuna, M. Balli, Ettore Bichisao, G. Bonciarelli, G. Ambroso, P. Malacarne, M. Indelli, Franco Pannuti, R. Cellerino
Publikováno v:
Cancer Chemotherapy and Pharmacology. 27:451-455
Drug plasma levels, metabolism data and clinical results were evaluated after the daily administration of either 500 or 1,000 mg aminoglutethimide (AG, Orimeten, Ciba-Geigy) plus hydrocortisone acetate (20 mg b. i. d.). A total of 34 patients with ad
Autor:
Daniele Bernardi, M. Mencoboni, Antonio Frassoldati, P. Tagliaferri, T. Raggi, Teresa Gamucci, Giovanni Rosti, G. Bonciarelli, R. Maisano, N. Salesi, E. Scelzi
Publikováno v:
Annals of Oncology. 26:vi121
Publikováno v:
Tumori. 82(3)
Despite the improvement of cancer treatments, unproven and useless therapies are widely adopted among cancer patients and their families. Little information is available on the actual magnitude of such a phenomenon.Two anonymous, similarly aimed surv
Publikováno v:
Haematologica. 79(2)
Primary vaginal non-Hodgkin lymphoma is really uncommon and may be misdiagnosed as inflammatory disease or solid cancer, so careful diagnostic procedures are needed, particularly as far as pathological and immunocytochemical evaluation is concerned.
Autor:
G. Bonciarelli, G. F. Garusi
Publikováno v:
Urologia Journal. 51:39-44
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Lancet (London, England). 2(8606)
Publikováno v:
Haematologica. 72(4)
Autor:
G, Ambrosini, M, Balli, G, Garusi, R, Demicheli, A, Jirillo, G, Bonciarelli, G, Bruscagnin, G, Fila, C, Bumma, F, Lacroix, F, Buzzi, F, Di Costanzo, D, Padalino, M, Brugia, F, Calabresi, M, Natali, G, Cartei, G, Chiesa, B, Blasina, E, Ciambellotti, G, Moro, S, D'Aquino, G, Altavilla, V, Adamo, D, De Maria, A M, Falchi, P, Bertoncelli, A, Farris, M, Fiorentino, A, Fornasiero, V, Fosser, O, Daniele, C M, Foggi, G B, Speranza, S, Sartori, E, Camilluzzi, L, Gallo, R, Poggio, V, Secondo, A, Gambi, F, Grignani, E, Capodicasa, M, Lopez, P, Papaldo, L, Di Lauro, P, Vici, G, Marenco, U, Folco, F, Bonanni, P, Marsilio, G, Palazzotto, A, Di Carlo, M P, Cusimano, G, Pastorino, C, Puccetti, M, Giusto, L, Rausa, N, Gebbia, S, Palmeri, N, D'Alessandro, F, Saccani, G, Becchi, G, Schieppati, I, Spinelli, A, Tagliagambe, M, Tonato, V, Minotti, A, Ardia, D, Viaro, P, De Micheli, G, Zingali, G, Sacchetti, C, Intini
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 6(6)
From February 1983 to January 1985, 497 patients with advanced breast cancer were randomly allocated to receive either epirubicin or doxorubicin in the following combination chemotherapy regimen: fluorouracil (5-FU) 500 mg/m2 intravenous (IV) on days